SkylineDx has announced a three-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB’s expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx’ strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
“We are extremely very pleased with this collaboration. VIB has done cutting edge biotech discoveries and has an impressive start-up portfolio,” says Dharminder Chahal, CEO SkylineDx. “With both our multi-disciplinary teams involved, I am confident that we can leverage each other’s strength and build a revolutionary pipeline together.”
The collaboration aims to progress high potential research projects into in vitro diagnostic device (IVD) development trajectories to create commercially viable products linked to unmet medical needs for global markets.
“Molecular diagnostics have the potential to tailor treatment decisions to individual patients, making therapy more effective and cost-efficient,” says Jérôme Van Biervliet, VIB’s managing director. “We look forward to working with SkylineDx to co-develop molecular diagnostics projects. SkylineDx’ unique expertise can tie in VIB’s discovered biomarkers to develop them into IVD products ready for the market.”
